Cancer Research: A Supercomputing Perspective

By Aaron Dubrow

May 31, 2017

Cancer, the second-leading cause of death in the U.S. after heart disease, kills more than 500,000 citizens per year, including about 2,000 children.

In 2016, then Vice President Joe Biden launched the Cancer Moonshot, saying: “I know that we can help solidify a genuine global commitment to end cancer as we know it today —  and inspire a new generation of scientists to pursue new discoveries and the bounds of human endeavor.”

The importance of high performance computing (HPC) in cancer research was recognized by the Cancer Moonshot Task Force report, and by then Vice President Joe Biden and Energy Secretary Ernie Monitz.

“Supercomputers are key to the Cancer Moonshot,” Monitz wrote. “These exceptionally high-powered machines have the potential to greatly accelerate the development of cancer therapies by finding patterns in massive datasets too large for human analysis. Supercomputers can help us better understand the complexity of cancer development, identify novel and effective treatments, and help elucidate patterns in vast and complex data sets that advance our understanding of cancer.”

With complex, non-linear signaling networks, multiscale dynamics from the quantum to the macro level, and giant, complex datasets of patient responses, cancer is quite possibly the ultimate in HPC problems.

“What could be more complicated and more important?” said J. Tinsley Oden, a computational researcher at The University of Texas at Austin applying uncertainty quantification to cancer treatment predictions. “At each step, it has the most complex features. It is really a garden of rich, important problems that are in the path of many of the developments that we’ve been working on for years.”

Infographic depicts TACC’s multi-domain approach to fighting cancer — click to expand

Hundreds of oncologists, biologists and computer scientists use the HPC systems at the Texas Advanced Computing Center (TACC) to understand the fundamental nature of cancer biology and to improve cancer treatments. Their work addresses a range of cancers types and treatment modalities, and spans applied or fundamental research.

Though diverse in their specific targets, the approaches they use can be loosely grouped into seven broad methodologies: molecular simulation; bioinformatics; mathematical modeling; computational treatment planning; quantum calculation; clinical trial design; and machine learning. The following sections describe and provide examples of each.

Molecular Simulations

Simulating protein and drug interactions at the molecular level enables scientists to understand the mechanics of cancer to design more effective treatments.

For Rommie Amaro, professor of Chemistry and Biochemistry at the University of California, San Diego, this means uncovering new pockets in tumor protein 53 (p53) — “the guardian of the genome” — which plays a crucial role in conserving the stability of DNA and preventing mutations.

The model of full-length p53 protein bound to DNA as a tetramer. The surface of each p53 monomer is depicted with a different color. [Courtesy: Özlem Demir, University of California, San Diego]
In approximately 50 percent of all human cancers, p53 is mutated and rendered inactive, therefore, reactivating mutant p53 using small molecules has been a long-sought-after anticancer therapeutic strategy.

In September 2016, writing in the journal Oncogene, Amaro reported results of the largest atomic-level simulation of the p53 to date — comprising more than 1.5 million atoms. The simulations, enabled by the Stampede supercomputer at TACC, helped identify new binding sites on the surface of the protein that could potentially reactivate p53.

“When most people think about cancer research they probably don’t think about computers,” she said. “But biophysical models are getting to the point where they have a great impact on the science.”

Virtual drug screening is another important HPC application for cancer research. Shuxing Zhang, professor of experimental therapeutics at MD Anderson Cancer Center, used molecule simulations on TACC’s Lonestar5 system to screen 1,448 Food and Drug Administration-approved small molecule drugs to determine which had the molecular features needed to bind and inhibit TNIK — an enzyme that plays a key role in cell signaling in colon cancer.

Zhang discovered that mebendazole, an FDA-approved drug that fights parasites, could effectively bind to TNIK and inhibit its enzymatic activity. He reported his results in Nature Scientific Reports in September 2016.

“Such advantages render the possibility of quickly translating the discovery into a clinical setting for cancer treatment in the near future,” Zhang wrote.

Bioinformatics

The human genome consists of three billion base pairs, so identifying single mutations by sight simply isn’t possible. For that reason, the field of bioinformatics — which uses computing and software to identify patterns and differences in biological data — has been an enormous boon for cancer researchers.

But bioinformatics is more than simple, one-to-one pattern matching.

A heat map showing differences in gene expression between primary tumors and cultured cell lines. Each row is a gene and each column is a tumor or cell sample. In the heat map, red indicates high expression and blue indicates low expression. NHA refers to normal human astrocytes, a star-shaped glial cell of the central nervous system. [Courtesy: Amelia Weber Hall, Iyer lab]
“When you move into multi-dimensional, time-series, or population-level studies, the algorithms can get a lot more computationally intensive,” said Matt Vaughn, TACC’s Director of Life Sciences Computing. “This requires resources like those at TACC, which help large numbers of researchers explore the complexity of cancer genomes by providing elastic, large-scale computing capability.”

For Vishy Iyer, a molecular biologist at The University of Texas at Austin (UT Austin), and his collaborators, access to TACC’s Stampede supercomputer helps them mine reams of data from The Cancer Genome Atlas to identify genetic variants and subtle correlations that affect gene expression in tumors.

“TACC has been vital to our analysis of cancer genomics data, both for providing the necessary computational power and the security needed for handling sensitive patient genomic datasets,” Iyer said.

In February 2016, Iyer and a team of researchers from UT Austin and MD Anderson Cancer Center reported in Nature Communications on a genome-wide transcriptome analysis of the two types of cells that make up the prostate gland. They identified cell-type-specific gene signatures that were associated with aggressive subtypes of prostate cancer and adverse clinical responses.

“This knowledge can be helpful in the development of more targeted therapies that seek to eliminate cancer at its origin,” Iyer said.

Using a similar methodology, Iyer and a team of researchers from UT Austin and the National Cancer Institute identified a transcription factor associated with an aggressive type of lymphoma that is highly correlated with poor therapeutic outcomes. They published their results in the Proceedings of the National Academy of Sciences in January 2016.

Whereas Iyer, an experienced HPC user, develops custom tools for his analyses, a much larger number of researchers access Stampede and comparable systems through scientific gateways. One prominent gateway is Galaxy, an open source bioinformatics platform that serves 30,000 researchers and runs more than 3,000 compute jobs a day.

Since 2014, TACC has powered the data analyses for a large percentage of Galaxy users, allowing researchers to solve tough problems in cases where their personal computer or campus cluster is not sufficient. Of those researchers, a significant subset use the site to analyze cancer genomes.

“Galaxy can be used to identify tumor mutations that drive cancer growth, find proteins that are overexpressed in a tumor, as well as for chemo-informatics and drug discovery,” said Jeremy Goecks, Assistant Professor of Biomedical Engineering and Computational Biology at Oregon Health and Science University and one of Galaxy’s principal investigators.

Goecks estimates that hundreds of researchers each year use the platform for cancer research, himself included. Because cancer patient data is closely protected, the bulk of this usage involves either publically available cancer data, or data on cancer cell lines – immortalized cells that reproduce in the lab and are used to study how cancer reacts to different drugs or conditions.

“This is an ideal marriage of TACC having tremendous computing power with scalable architecture and Galaxy coming along and saying, we’re going to go the last mile and make sure that people who can’t normally use this hardware are able to.”

Mathematical Modeling

While some researchers believe bioinformatics will rapidly advance the understanding and treatment of cancer, others think a better approach is to mathematize cancer: to uncover the fundamental formulas that represent how cancer, in its varied forms, behaves.

At the Center for Computational Oncology at UT Austin, researchers are developing complex computer models to predict how cancer will progress in a specific individual.

Each factor involved in the tumor response — whether it is the speed with which chemotherapeutic drugs reach the tissue or the degree to which cells signal each other to grow — is characterized by a mathematical equation that captures its essence. These models are combined and parameterized and initialized with patient-specific data.

In April 2017, writing in the Journal of The Royal Society Interface, Thomas Yankeelov and collaborators at UT Austin and Vanderbilt University, showed that they can predict how brain tumors (gliomas) will grow in mice with greater accuracy than previous models by including factors like the mechanical forces acting on the cells and the tumor’s cellular heterogeneity.

To develop and implement their mathematically complex models, the center’s scientists use TACC’s supercomputers, which enable them to solve bigger problems that they otherwise could and reach solutions far faster.

Recently, the group has begun a clinical study to predict, after one treatment, how an individual’s cancer will progress, and use those predictions to plan the future course of treatment.

“There are not enough resources or patients to sort this problem out because there are too many variables. It would take until the end of time,” Yankeelov said. “But if you have a model that can recapitulate how tumors grow and respond to therapy, then it becomes a classic engineering optimization problem. ‘I have this much drug and this much time. What’s the best way to give it to minimize the number of tumor cells for the longest amount of time?’”

Computing at TACC helps Yankeelov accelerate his research. “We can solve problems in a few minutes that would take us three weeks to do using the resources at our old institution,” he said. “It’s phenomenal.”

Quantum Calculations

X-ray radiation is the most frequently used form of radiation therapy, but a new treatment is emerging that uses a beam of protons to kill cancer cells with minimum damage on surrounding tissues.

“As happens in cancer therapy, we know empirically that it works, but we don’t know why,” said Jorge A. Morales, a professor of chemistry at Texas Tech University and a leading proponent of the computational analysis of proton therapy. “To do experiments with human subjects is dangerous, so the best way is through computer simulation.”

Computational experiments can mimic the dynamics of the proton-cell interactions without causing damage to a patient and can reveal what happens when the proton beam and cells collide from start to finish, with atomic-level accuracy. Morales has been simulating proton-cell chemical reactions using quantum dynamics models on TACC’s Stampede supercomputer to investigate the fundamentals of the process.

His studies, reported in PLOS One in March 2017, as well as in Molecular Physics, and Chemical Physics Letters (2015 and 2014 respectively), have determined the basic byproducts of protons colliding with water within the cell, and with nucleotides and clusters of DNA bases – the basic units of DNA. The studies shed light on how the protons and their water radiolysis products damage DNA.

Though fundamental in nature, the insights and data that Morales’ simulations produce help researchers understand proton cancer therapy at the quantum level, and help modulate factors like dosage and beam direction.

“These simulations will bring about a unique way to understand and control proton cancer therapy that, at a very low cost, will help to drastically improve the treatment of cancer patients without risking human subjects,” Morales said.

Computational Treatment Planning

Wei Liu, a researcher at the Mayo Clinic, also studies proton therapy, but he looks at the treatment from a clinical perspective.

In comparison with current radiation procedures, proton therapy saves healthy tissue in front of and behind the tumor. It is particularly effective when irradiating tumors near sensitive organs where stray beams can be particularly damaging.

However, the pinpoint accuracy required by the protein beam, which is its greatest advantage, means that it must be precisely calibrated and that discrepancies from the ideal (whether from device, human error or even patient breathing) must be taken into consideration.

Writing in Medical Physics in January 2017, Liu and his collaborators showed that their “chance-constrained model” was better at sparing organs at risk than current methods.

“Each time, we try to mathematically generate a good plan,” he said. “There are 25,000 variables or more, so generating a plan that is robust to these mistakes and can still get the proper dose distribution to the tumor is a large-scale optimization problem.”

The researchers used the Lonestar5 supercomputer at TACC to generate treatment plans that minimize the risk and uncertainties involved in proton beam therapy.

“It’s very computationally expensive to generate a plan in a reasonable timeframe,” he continued. “Without a supercomputer, we can do nothing.”

Computational Trial Design

Another way researchers use TACC’s advanced computers is to design clinical trials that can better determine which combination of dosages will be most effective, specifically for the biological agents used in immunotherapy, which work very differently from chemotherapy and radiation.

Writing in the Journal of the Royal Statistics Society Series C (Applied Statistics), Chunyan Cai, assistant professor of biostatistics at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) described her efforts using Lonestar5 to identify biologically optimal dose combinations for agents that target the PI3K/AKT/mTOR signaling pathway, which has been associated with several genetic aberrations related to the promotion of cancer.

Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Immunotherapy fights cancer by supercharging the immune system’s natural defenses (include T-cells) or contributing additional immune elements that can help the body kill cancer cells. HPC is helping researchers better understand how immunotherapeutic agents can be used effectively [Courtesy: NIAID]
“Our research is motivated by a drug combination trial at MD Anderson Cancer Center for patients diagnosed with relapsed lymphoma,” Cai said. “The trial combined two novel biological agents that target two different components in the PI3K/AKT/mTOR signaling pathway.”

They investigated six different dose-toxicity and dose-efficacy scenarios and carried out 2,000 simulated trials for each of the designs.

Based on those simulations, she concluded that “the design proposed has desirable operating characteristics in identifying the biologically optimal dose combination under various patterns of dose–toxicity and dose–efficacy relationships.”

The research is leading to new, safer and more effective ways to test combinations of immunotherapeutic agents.

Machine Learning

A final, and truly radical, way that researchers are using HPC for cancer research is through the application of machine and deep learning.

The Eberlin research group at UT Austin develops clinical applications of ambient mass spectrometry for cancer diagnosis. They create tools and techniques to assist surgeons in distinguishing between normal and cancer tissue during tumor resection operations.

To do so, they have had to develop statistical methods that can analyze and interpret large amount of mass spectrometry data gathered from clinical samples.

Jonathan Young, a post-doctoral research in the group, is building machine learning classifiers to reliably predict whether a given tissue sample is cancer or normal, and if it is indeed cancer, which specific subtype the tumor belongs to.

Young uses the Maverick system at TACC, which contains a large number of NVIDIA GPUs, to develop and implement the machine learning algorithms. “The large memory capacity of Maverick is well suited for our extensive datasets, and the parallelization capability will aid in parameter sweeps during the training of classifiers,” Young said.

Young will present his work at the American Society for Mass Spectrometry (ASMS) Annual Conference this June.

Another example of the application of machine learning to cancer can be found in the work of Daniel Lobo, an assistant professor of biology and computer science at the University of Maryland, Baltimore County (UMBC). He is using machine learning to map out the cellular communication networks that underlie cancer, and to design methods to disrupt them.

In their January 2017 paper in Scientific Reports, Lobo and collaborators showed that machine learning can uncover the cellular networks that determine pigmentation in tadpoles and reverse-engineering never-before-seen coloration. Their work was facilitated by Stampede, which enabled the team to run billions of simulations to identify models of the cellular network and the means of altering it.

Lobo’s lab is applying the method to cancer research to determine what type of interventions might stop metastasis in its tracks without damaging other cells.

“Traditional approaches like chemotherapy attack the cells that grow the most, but leave cells that are signaling others to grow and that may be the most important,” Lobo says. “We’re using machine learning to find out the communication networks between these cells and hopefully to discover a treatment that can cause the tumor to collapse.”

“Getting a true understanding, given the complexity of the information, without some assistance from machine learning, is probably hopeless,” said Michael Levin, Lobo’s collaborator. “I think it’s inevitable that we use machine learning to enrich scientific and biomedical discovery.”

From patient-specific treatments to immunology to drug discovery, advanced computing is accelerating the basic and applied science underlying our understanding of cancer and the development and application of cancer treatments.

If scientists are the rocket in the cancer moonshot, HPC processing power is the jet fuel.

About the Author

Aaron Dubrow joined TACC in October 2007 as the Science and Technology Writer with the responsibility of reporting on the myriad of research and development projects undertaken by TACC.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

What’s New in HPC Research: September (Part 1)

September 18, 2018

In this new bimonthly feature, HPCwire will highlight newly published research in the high-performance computing community and related domains. From exascale to quantum computing, the details are here. Check back every Read more…

By Oliver Peckham

House Passes $1.275B National Quantum Initiative

September 17, 2018

Last Thursday the U.S. House of Representatives passed the National Quantum Initiative Act (NQIA) intended to accelerate quantum computing research and development. Among other things it would establish a National Quantu Read more…

By John Russell

Nvidia Accelerates AI Inference in the Datacenter with T4 GPU

September 14, 2018

Nvidia is upping its game for AI inference in the datacenter with a new platform consisting of an inference accelerator chip--the new Turing-based Tesla T4 GPU--and a refresh of its inference server software packaged as Read more…

By George Leopold

HPE Extreme Performance Solutions

Introducing the First Integrated System Management Software for HPC Clusters from HPE

How do you manage your complex, growing cluster environments? Answer that big challenge with the new HPC cluster management solution: HPE Performance Cluster Manager. Read more…

IBM Accelerated Insights

A Crystal Ball for HPC

People are notoriously bad at predicting the future.  This very much includes experts. In the Forbes article “Why Most Predictions Are So Bad” Philip Tetlock discusses the largest and best-known test of the accuracy of expert predictions which show that any experts would do better if they make random guesses. Read more…

NSF Highlights Expanded Efforts for Broadening Participation in Computing

September 13, 2018

Today, the Directorate of Computer and Information Science and Engineering (CISE) of the NSF released a letter highlighting the expansion of its broadening participation in computing efforts. The letter was penned by Jam Read more…

By Staff

House Passes $1.275B National Quantum Initiative

September 17, 2018

Last Thursday the U.S. House of Representatives passed the National Quantum Initiative Act (NQIA) intended to accelerate quantum computing research and developm Read more…

By John Russell

Nvidia Accelerates AI Inference in the Datacenter with T4 GPU

September 14, 2018

Nvidia is upping its game for AI inference in the datacenter with a new platform consisting of an inference accelerator chip--the new Turing-based Tesla T4 GPU- Read more…

By George Leopold

DeepSense Combines HPC and AI to Bolster Canada’s Ocean Economy

September 13, 2018

We often hear scientists say that we know less than 10 percent of the life of the oceans. This week, IBM and a group of Canadian industry and government partner Read more…

By Tiffany Trader

Rigetti (and Others) Pursuit of Quantum Advantage

September 11, 2018

Remember ‘quantum supremacy’, the much-touted but little-loved idea that the age of quantum computing would be signaled when quantum computers could tackle Read more…

By John Russell

How FPGAs Accelerate Financial Services Workloads

September 11, 2018

While FSI companies are unlikely, for competitive reasons, to disclose their FPGA strategies, James Reinders offers insights into the case for FPGAs as accelerators for FSI by discussing performance, power, size, latency, jitter and inline processing. Read more…

By James Reinders

Update from Gregory Kurtzer on Singularity’s Push into FS and the Enterprise

September 11, 2018

Container technology is hardly new but it has undergone rapid evolution in the HPC space in recent years to accommodate traditional science workloads and HPC systems requirements. While Docker containers continue to dominate in the enterprise, other variants are becoming important and one alternative with distinctly HPC roots – Singularity – is making an enterprise push targeting advanced scale workload inclusive of HPC. Read more…

By John Russell

At HPC on Wall Street: AI-as-a-Service Accelerates AI Journeys

September 10, 2018

AIaaS – artificial intelligence-as-a-service – is the technology discipline that eases enterprise entry into the mysteries of the AI journey while lowering Read more…

By Doug Black

No Go for GloFo at 7nm; and the Fujitsu A64FX post-K CPU

September 5, 2018

It’s been a news worthy couple of weeks in the semiconductor and HPC industry. There were several HPC relevant disclosures at Hot Chips 2018 to whet appetites Read more…

By Dairsie Latimer

TACC Wins Next NSF-funded Major Supercomputer

July 30, 2018

The Texas Advanced Computing Center (TACC) has won the next NSF-funded big supercomputer beating out rivals including the National Center for Supercomputing Ap Read more…

By John Russell

IBM at Hot Chips: What’s Next for Power

August 23, 2018

With processor, memory and networking technologies all racing to fill in for an ailing Moore’s law, the era of the heterogeneous datacenter is well underway, Read more…

By Tiffany Trader

Requiem for a Phi: Knights Landing Discontinued

July 25, 2018

On Monday, Intel made public its end of life strategy for the Knights Landing "KNL" Phi product set. The announcement makes official what has already been wide Read more…

By Tiffany Trader

CERN Project Sees Orders-of-Magnitude Speedup with AI Approach

August 14, 2018

An award-winning effort at CERN has demonstrated potential to significantly change how the physics based modeling and simulation communities view machine learni Read more…

By Rob Farber

ORNL Summit Supercomputer Is Officially Here

June 8, 2018

Oak Ridge National Laboratory (ORNL) together with IBM and Nvidia celebrated the official unveiling of the Department of Energy (DOE) Summit supercomputer toda Read more…

By Tiffany Trader

New Deep Learning Algorithm Solves Rubik’s Cube

July 25, 2018

Solving (and attempting to solve) Rubik’s Cube has delighted millions of puzzle lovers since 1974 when the cube was invented by Hungarian sculptor and archite Read more…

By John Russell

AMD’s EPYC Road to Redemption in Six Slides

June 21, 2018

A year ago AMD returned to the server market with its EPYC processor line. The earth didn’t tremble but folks took notice. People remember the Opteron fondly Read more…

By John Russell

MLPerf – Will New Machine Learning Benchmark Help Propel AI Forward?

May 2, 2018

Let the AI benchmarking wars begin. Today, a diverse group from academia and industry – Google, Baidu, Intel, AMD, Harvard, and Stanford among them – releas Read more…

By John Russell

Leading Solution Providers

SC17 Booth Video Tours Playlist

Altair @ SC17

Altair

AMD @ SC17

AMD

ASRock Rack @ SC17

ASRock Rack

CEJN @ SC17

CEJN

DDN Storage @ SC17

DDN Storage

Huawei @ SC17

Huawei

IBM @ SC17

IBM

IBM Power Systems @ SC17

IBM Power Systems

Intel @ SC17

Intel

Lenovo @ SC17

Lenovo

Mellanox Technologies @ SC17

Mellanox Technologies

Microsoft @ SC17

Microsoft

Penguin Computing @ SC17

Penguin Computing

Pure Storage @ SC17

Pure Storage

Supericro @ SC17

Supericro

Tyan @ SC17

Tyan

Univa @ SC17

Univa

Pattern Computer – Startup Claims Breakthrough in ‘Pattern Discovery’ Technology

May 23, 2018

If it weren’t for the heavy-hitter technology team behind start-up Pattern Computer, which emerged from stealth today in a live-streamed event from San Franci Read more…

By John Russell

Sandia to Take Delivery of World’s Largest Arm System

June 18, 2018

While the enterprise remains circumspect on prospects for Arm servers in the datacenter, the leadership HPC community is taking a bolder, brighter view of the x86 server CPU alternative. Amongst current and planned Arm HPC installations – i.e., the innovative Mont-Blanc project, led by Bull/Atos, the 'Isambard’ Cray XC50 going into the University of Bristol, and commitments from both Japan and France among others -- HPE is announcing that it will be supply the United States National Nuclear Security Administration (NNSA) with a 2.3 petaflops peak Arm-based system, named Astra. Read more…

By Tiffany Trader

D-Wave Breaks New Ground in Quantum Simulation

July 16, 2018

Last Friday D-Wave scientists and colleagues published work in Science which they say represents the first fulfillment of Richard Feynman’s 1982 notion that Read more…

By John Russell

Intel Pledges First Commercial Nervana Product ‘Spring Crest’ in 2019

May 24, 2018

At its AI developer conference in San Francisco yesterday, Intel embraced a holistic approach to AI and showed off a broad AI portfolio that includes Xeon processors, Movidius technologies, FPGAs and Intel’s Nervana Neural Network Processors (NNPs), based on the technology it acquired in 2016. Read more…

By Tiffany Trader

Intel Announces Cooper Lake, Advances AI Strategy

August 9, 2018

Intel's chief datacenter exec Navin Shenoy kicked off the company's Data-Centric Innovation Summit Wednesday, the day-long program devoted to Intel's datacenter Read more…

By Tiffany Trader

TACC’s ‘Frontera’ Supercomputer Expands Horizon for Extreme-Scale Science

August 29, 2018

The National Science Foundation and the Texas Advanced Computing Center announced today that a new system, called Frontera, will overtake Stampede 2 as the fast Read more…

By Tiffany Trader

GPUs Power Five of World’s Top Seven Supercomputers

June 25, 2018

The top 10 echelon of the newly minted Top500 list boasts three powerful new systems with one common engine: the Nvidia Volta V100 general-purpose graphics proc Read more…

By Tiffany Trader

The Machine Learning Hype Cycle and HPC

June 14, 2018

Like many other HPC professionals I’m following the hype cycle around machine learning/deep learning with interest. I subscribe to the view that we’re probably approaching the ‘peak of inflated expectation’ but not quite yet starting the descent into the ‘trough of disillusionment. This still raises the probability that... Read more…

By Dairsie Latimer

  • arrow
  • Click Here for More Headlines
  • arrow
Do NOT follow this link or you will be banned from the site!
Share This